Home

Linda Grais

CIK 1413306 · President and CEO · last filed 2026-08-12

Linda Grais is a President and CEO who has filed 59 SEC Form 4 insider transactions across 5 companies since 2009. The most recent filing, for ICLR, was dated Aug 12, 2026. Across all open-market trades the lifetime net is −$1.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions. 5 SEC filings were submitted jointly with Christopher B Ehrlich.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.16M

Companies

5

Total Filings

59

Lifetime Open-Market Net

-$1.67M

Filer Profile

Reported Address
86 ALEJANDRA AVE
ATHERTON, CA 94027
Formerly Known As
Grais Linda S (2007–2020)
Related Filers
Christopher B Ehrlich — 5 joint filings, latest 2010-08-10
KHALED NASR — 5 joint filings, latest 2010-08-10
Douglas A Pepper — 5 joint filings, latest 2010-08-10
InterWest Management Partners IX, LLC — 3 joint filings, latest 2007-11-21
Nina S Kjellson — 3 joint filings, latest 2007-11-21
InterWest Partners IX, LP — 2 joint filings, latest 2010-08-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ICLR Director 6,162 $164.85 $1.02M -$138.2K 1 2026-08-12
CRVS Director 10,000 $14.39 $143.9K $24.5K 14 2026-06-15
Oruka Therapeutics, Inc. (ABIO) Delisted Director 54 $28.80 $1.6K -$1.55M 14 2024-01-31
PRA Health Sciences, Inc. (PRAH) Delisted Director 0 $165.21 $0 $0 8 2021-07-01
Zosano Pharma Corp (ZSAN) Delisted Director 643 $0.56 $359 $0 5 2021-06-14

Recent Filings

59 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-12 ICLR Mixed +891 -$138.2K EDGAR
2026-08-11 ICLR Notice (144) −841 -$138.2K EDGAR
2026-06-15 CRVS Grant (A) — $0 EDGAR
2025-06-16 CRVS Grant (A) — $0 EDGAR
2025-05-23 ICLR Notice (144) −334 -$42.4K EDGAR
2024-06-17 CRVS Grant (A) — $0 EDGAR
2024-05-23 ICLR Notice (144) −450 -$143.3K EDGAR
2024-01-31 Oruka Therapeutics, Inc. (ABIO) Delisted Grant (A) — $0 EDGAR
2023-12-08 CRVS Grant (A) — $0 EDGAR
2023-06-20 CRVS Grant (A) — $0 EDGAR
Showing 1–10 of 59
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.